SCHEMBL2580883

SCHEMBL2580883

NCCCCCCOC[C@H]1O[C@@H](n2ccc(N)nc2=O)C[C@@H]1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.59
P2RY2 P41231 3/20 0.49
P2RY4 P51582 3/20 0.49
P2RY6 Q15077 2/20 0.49
LMNA P02545 3/20 0.43
PDE3A Q14432 3/20 0.43
CACNA1F O60840 2/20 0.43
ALB P02768 2/20 0.43
MAPT P10636 2/20 0.43
CACNA1D Q01668 2/20 0.43
CACNA1S Q13698 2/20 0.43
CACNA1C Q13936 2/20 0.43
ADRB1 P08588 1/20 0.43
DNMT1 P26358 1/20 0.43
THRB P10828 1/20 0.43
MTOR P42345 1/20 0.43
MDM2 Q00987 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
POLG P54098 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8660989 0.92 POLB (0.59) POLBP2RY2P2RY4P2RY6LMNA
SCHEMBL7772982 0.92 POLB (0.63) POLBP2RY2P2RY4P2RY6LMNA
SCHEMBL5413913 0.90 POLB (0.59) POLBP2RY2P2RY4P2RY6LMNA
SCHEMBL5155763 0.90 POLB (0.59) POLBP2RY2P2RY4P2RY6LMNA
SCHEMBL8664179 0.89 POLB (0.57) POLBP2RY2P2RY4P2RY6LMNA
SCHEMBL3933966 0.87 POLB (0.57) POLBP2RY2P2RY4P2RY6LMNA
SCHEMBL145870 0.85 POLB (0.67) POLBP2RY2P2RY4P2RY6POLG
SCHEMBL13111591 0.85 POLB (0.67) POLBP2RY2P2RY4P2RY6POLG
SCHEMBL13127046 0.85 POLB (0.67) POLBP2RY2P2RY4P2RY6POLG
SCHEMBL4971920 0.85 POLB (0.66) POLBP2RY2P2RY4P2RY6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048659-B1 Conjugated polymer tag complexes LEIF ROBERT C 2011-11-01 US disclosed
US-6825331-B2 DIAGNOSTIC HYBRIDIZATION PROBES; BIOCHEMICAL CONJUGATION ISIS PHARMACEUTICALS, INC. 2004-11-30 US disclosed
US-20030113769-A1 Aminooxy functionalized oligomers, oligomer arrays and methods of using them IONIS PHARMACEUTICALS, INC. 2003-06-19 US disclosed
US-6576752-B1 Oligonucleotide comprising a plurality of nucleotide units of given structure; useful for diagnostic, therapeutic and investigative purposes ISIS PHARMACEUTICALS, INC. 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030113769-A1 Aminooxy functionalized oligomers, oligomer arrays and methods of using them RNGTT, RNMT, DCLRE1B POLB 32/4885P2RY2 3727/4885P2RY4 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.